Publication:
Effective diagnosis of Alzheimer's disease by means of large margin-based methodology.

dc.contributor.authorChaves, Rosa
dc.contributor.authorRamírez, Javier
dc.contributor.authorGórriz, Juan M
dc.contributor.authorIllán, Ignacio A
dc.contributor.authorGómez-Río, Manuel
dc.contributor.authorCarnero, Cristobal
dc.contributor.authoraffiliation[Chaves,R; Ramírez,J; Górriz,JM; Illán,IA] Department of Signal Theory, Networking and Communications, University of Granada. [Gómez-Río,M] Department of Nuclear Medicine, University Hospital Virgen de las Nieves, Granada, Spain. [Carnero,C] Department of Neurology, University Hospital Virgen de las Nieves, Granada, Spain.es
dc.contributor.funderThis work was partly supported by the MICINN of Spain under the TEC2008-02113 and TEC2012-34306 project and the Consejeria de Innovacion, Ciencia y Empresa (Junta de Andalucia, Spain) under the Excellence Projects P07-TIC-02566, P09-TIC- 4530 and P11-TIC-7103. The PET data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Amorfix Life Sciences Ltd., AstraZeneca, Bayer HealthCare; BioClinica, Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Eisai Inc., Elan Pharmaceuticals Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc., GE Healthcare, Innogenetics, N.V., IXICO Ltd., Janssen Alzheimer Immunotherapy Research and Development, LLC., Johnson and Johnson Pharmaceutical Research and Development LLC., Medpace, Inc., Merck and Pfizer Inc., Servier, Synarc Inc., and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.
dc.contributor.groupThe Alzheimer’s Disease Neuroimaging Initiativees
dc.date.accessioned2013-11-25T13:38:39Z
dc.date.available2013-11-25T13:38:39Z
dc.date.issued2012-07-31
dc.descriptionComparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;es
dc.description.abstractBACKGROUND Functional brain images such as Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) have been widely used to guide the clinicians in the Alzheimer's Disease (AD) diagnosis. However, the subjectivity involved in their evaluation has favoured the development of Computer Aided Diagnosis (CAD) Systems. METHODS It is proposed a novel combination of feature extraction techniques to improve the diagnosis of AD. Firstly, Regions of Interest (ROIs) are selected by means of a t-test carried out on 3D Normalised Mean Square Error (NMSE) features restricted to be located within a predefined brain activation mask. In order to address the small sample-size problem, the dimension of the feature space was further reduced by: Large Margin Nearest Neighbours using a rectangular matrix (LMNN-RECT), Principal Component Analysis (PCA) or Partial Least Squares (PLS) (the two latter also analysed with a LMNN transformation). Regarding the classifiers, kernel Support Vector Machines (SVMs) and LMNN using Euclidean, Mahalanobis and Energy-based metrics were compared. RESULTS Several experiments were conducted in order to evaluate the proposed LMNN-based feature extraction algorithms and its benefits as: i) linear transformation of the PLS or PCA reduced data, ii) feature reduction technique, and iii) classifier (with Euclidean, Mahalanobis or Energy-based methodology). The system was evaluated by means of k-fold cross-validation yielding accuracy, sensitivity and specificity values of 92.78%, 91.07% and 95.12% (for SPECT) and 90.67%, 88% and 93.33% (for PET), respectively, when a NMSE-PLS-LMNN feature extraction method was used in combination with a SVM classifier, thus outperforming recently reported baseline methods. CONCLUSIONS All the proposed methods turned out to be a valid solution for the presented problem. One of the advances is the robustness of the LMNN algorithm that not only provides higher separation rate between the classes but it also makes (in combination with NMSE and PLS) this rate variation more stable. In addition, their generalization ability is another advance since several experiments were performed on two image modalities (SPECT and PET).es
dc.description.versionYeses
dc.identifier.citationChaves R, Ramírez J, Górriz JM, Illán IA, Gómez-Río M, Carnero C. Effective diagnosis of Alzheimer's disease by means of large margin-based methodology. BMC Med Inform Decis Mak; 12:79es
dc.identifier.doi10.1186/1472-6947-12-79
dc.identifier.essn1472-6947
dc.identifier.pmcPMC3512495
dc.identifier.pmid22849649
dc.identifier.urihttp://hdl.handle.net/10668/1395
dc.journal.titleBMC medical informatics and decision making
dc.language.isoen
dc.publisherBioMed Centrales
dc.relation.publisherversionhttp://www.biomedcentral.com/1472-6947/12/79/abstractes
dc.rights.accessRightsopen access
dc.subjectAncianoes
dc.subjectAlgoritmoses
dc.subjectEnfermedad de Alzheimeres
dc.subjectInteligencia Artificiales
dc.subjectInterpretación Estadística de Datoses
dc.subjectDiagnóstico Precozes
dc.subjectFemeninoes
dc.subjectNeuroimagen Funcionales
dc.subjectInterpretación de Imagen Asistida por Computadores
dc.subjectTomografía de Emisión de Positroneses
dc.subjectAnálisis de Componente Principales
dc.subjectRadiofármacoses
dc.subjectSensibilidad y Especificidades
dc.subjectEspañaes
dc.subjectTomografía Computarizada de Emisión de Fotón Únicoes
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Agedes
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Aged::Aged, 80 and overes
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Mathematical Concepts::Algorithmses
dc.subject.meshMedical Subject Headings::Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Dementia::Alzheimer Diseasees
dc.subject.meshMedical Subject Headings::Information Science::Information Science::Computing Methodologies::Artificial Intelligencees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Decision Support Techniques::Data Interpretation, Statisticales
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Early Diagnosises
dc.subject.meshMedical Subject Headings::Check Tags::Femalees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Neuroimaging::Functional Neuroimaginges
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnosis, Computer-Assisted::Image Interpretation, Computer-Assistedes
dc.subject.meshMedical Subject Headings::Check Tags::Femalees
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Agedes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, Emission-Computed::Positron-Emission Tomographyes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Principal Component Analysises
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Specialty Uses of Chemicals::Laboratory Chemicals::Indicators and Reagents::Radiopharmaceuticalses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Sensitivity and Specificityes
dc.subject.meshMedical Subject Headings::Geographicals::Geographic Locations::Europe::Spaines
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, Emission-Computed::Tomography, Emission-Computed, Single-Photones
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adultes
dc.titleEffective diagnosis of Alzheimer's disease by means of large margin-based methodology.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Chaves_EffectiveDiagnosis.pdf
Size:
610.54 KB
Format:
Adobe Portable Document Format
Description: